

Type of respondents	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
OS Participants .....	86,886	1.4059	.173	21,133
Next-of-kin .....	2,916	1	.0835	243
Physician's Office Staff .....	43	1	.0835	4
Total .....				21,380

The annualized cost burden is \$213,948.

There are no annual Capital Costs, Operating Costs and/or Maintenance Costs to report.

*Request for Comments:* Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

*For Further Information Contact:* To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Linda Pottern, Project Officer, Women's Health Initiative Program Office, 6705 Rockledge Drive, 1 Rockledge Centre, Suite 300, MSC 7966, Bethesda, MD 20892-7966, or call (301) 402-2900 or e-mail your request, including your address to: [Linda\\_Pottern@nih.gov](mailto:Linda_Pottern@nih.gov).

*Comments Due Date:* Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: September 11, 2002.

**Jacques E. Rossouw,**

*Acting Director, Women's Health Initiative.*  
[FR Doc. 02-23873 Filed 9-19-02; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

#### New Tumor Suppressor Gene, p28ING5

Dr. Curtis C. Harris *et al.* (NCI)  
DHHS Reference No. E-300-01/0 filed January 23, 2001

*Licensing Contact:* Catherine Joyce; 301/496-7735 ext. 258; e-mail: [joycec@od.nih.gov](mailto:joycec@od.nih.gov)

This technology pertains to the discovery of a new member of the ING (inhibitor growth) family of putative tumor suppressor genes, p28ING5. p28ING5 was identified by homology to the tumor suppressor gene p33ING1. Over-expression of the ING5 protein causes cell cycle arrest in human cancer cell lines and ING5 expression varies between cancer cell lines. Detection of ING5 gene or protein expression could potentially be used for cancer diagnosis and ING5 could be used as a medicant.

The above-mentioned invention is available for licensing on an exclusive or non-exclusive basis.

#### HGC-1, A Gene Encoding a Member of the Olfactomedin-Related Protein Family

Griffin P. Rodgers, Wen-Li Liu, Jiachang Zhang (NIDDK)

U.S. Provisional Patent Application 60/338,759 (E-166-01/0) filed December 7, 2001

*Licensing Contact:* Brenda Hefti; 301/496-7736 ext. 206; e-mail: [heftib@od.nih.gov](mailto:heftib@od.nih.gov)

The current technology embodies a newly identified gene, Human Granulocyte Colony-Stimulating Factor-Stimulated-Clone-1 (hGC-1) that has been cloned and characterized, and its protein sequence has been deduced. The gene is expressed in the bone marrow, prostate, small intestine, colon, and stomach, and has been mapped to chromosome 13 in a region that contains a tumor suppressor gene cluster. The gene is found to be selectively present in normal human myeloid lineage cells and is believed to play a role in allowing lymphocytes to differentiate properly. It is believed that the gene may be used as a selective marker for human prostate cancer, multiple myeloma, B-cell chronic lymphocytic leukemia and other types of cancer and can be used diagnostically as well as in therapeutic screening activities.

#### Modulating IL-13 Activity Using Mutated IL-13 Molecules That Are Antagonists or Agonists of IL-13

R. Puri, Y. Oshima, and B. Joshi (FDA)  
PCT Application PCT/US00/31044 (E-032-00/2) filed November 10, 2000, and claiming priority to a U.S. Provisional application filed November 11, 1999

*Licensing Contact:* Brenda Hefti; 301/496-7736 ext. 206; e-mail: [heftib@od.nih.gov](mailto:heftib@od.nih.gov)

The present invention provides antagonists and agonists of IL-13 activity. The antagonists can be used to reduce or end symptoms in conditions, such as asthma, allergic rhinitis, atopic dermatitis, parasitic infections, pulmonary fibrosis, and others in which

IL-13 is an initiator, mediator or enhancer of the abnormal state. The agonists can also be used as reagents in the maturation of monocytes into dendritic cells, or to pre-treat bone marrow stem cell donors to reduce GVH disease. The antagonists can be used to slow the growth of cells in cancers for which IL-13 is an autocrine growth factor.

This invention also claims IL-13 receptor binding molecules with affinity for the IL-13 receptor at least three times greater than that exhibited by wild type IL-13. Finally, this invention claims methods and compositions for specifically delivering an effector molecule to a tumor cell by chimeric molecules comprising the effector molecule (plant or bacterial toxin, chemotherapeutic agents or antibiotics) and an IL-13 receptor binding molecule (antagonists or agonists), and pharmaceutical compositions thereof.

Dated: September 12, 2002.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 02-23875 Filed 9-19-02; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of the Director National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Office of AIDS Research Advisory Council.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* Office of AIDS Research Advisory Council.

*Date:* October 1-2, 2002.

*Time:* 9 a.m. to 12 p.m.

*Agenda:* A Report of the Director addressing OAR initiatives. The topic of the meeting will be "HIV/AIDS Research Needs in the Caribbean Basin."

*Place:* 9000 Rockville Pike, Building 31C, Conference Room 6C10, Bethesda, MD 20892.

*Contact Person:* Veronica Leftwich, Program Analyst, Office of AIDS Research, National Institutes of Health, Building 2, Room 4W11, Bethesda, MD 20892, (301) 435-7698.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Information is also available on the Institute's/Center's home page: <http://www.nih.gov/od/oar/index.htm>, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program, National Institutes of Health, HHS)

Dated: September 16, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-23952 Filed 9-19-02; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Complementary & Alternative Medicine; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Complementary and Alternative Medicine Special Emphasis Panel, CAM and Oncology.

*Date:* October 21-22, 2002.

*Time:* 8 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn, 8120 Wisconsin Ave., Bethesda, MD 20814.

*Contact Person:* Carol Pontzer, PhD, Scientific Review Administrator, National Center for Complementary and Alternative Medicine, 6707 Democracy Blvd., Bethesda, MD 20892.

Dated: September 11, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-23871 Filed 9-19-02; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Complementary & Alternative Medicine; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Complementary and Alternative Medicine Special Emphasis Panel, Basic Science SEP.

*Date:* October 10, 2002.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Marriott, 6711 Democracy Boulevard, Bethesda, MD 20817.

*Contact Person:* Dale Birkle, PhD, Scientific Review Administrator, NIH/NCCAM, 6707 Democracy Blvd, Democracy Two Building, Suite 401, Bethesda, MD 20892, (301) 451-6570, [birkled@mail.nih.gov](mailto:birkled@mail.nih.gov).

Dated: September 11, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-23872 Filed 9-19-02; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the